[{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teikoku Pharma Granted FDA Fast Track Designation for TPU-006, a Novel 4-day Dexmedetomidine Transdermal System for Post Operative Pain Management","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Link Healthcare Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm\u00ae in China on May 8, 2024","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Teikoku Pharma USA
TPU-006 is an investigational transdermal system that delivers dexmedetomidine, a selective α2-adrenergic agonist, for up to four days from a single application, which is investigated for the treatment of Post Operative Pain.